Copyright Reports & Markets. All rights reserved.

Global HCC (Hepatocellular Carcinoma) Biomarker Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of HCC (Hepatocellular Carcinoma) Biomarker by Type
    • 1.3.1 Overview: Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global HCC (Hepatocellular Carcinoma) Biomarker Consumption Value Market Share by Type in 2025
    • 1.3.3 Alpha-fetoprotein (AFP)
    • 1.3.4 Des-γ-carboxy Prothrombin (DCP)
    • 1.3.5 Others
  • 1.4 Global HCC (Hepatocellular Carcinoma) Biomarker Market by Application
    • 1.4.1 Overview: Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospitals
    • 1.4.3 Clinics
    • 1.4.4 Others
  • 1.5 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size & Forecast
  • 1.6 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast by Region
    • 1.6.1 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region, (2021-2032)
    • 1.6.3 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size and Prospect (2021-2032)
    • 1.6.4 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size and Prospect (2021-2032)
    • 1.6.6 South America HCC (Hepatocellular Carcinoma) Biomarker Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 FUJIFILM
    • 2.1.1 FUJIFILM Details
    • 2.1.2 FUJIFILM Major Business
    • 2.1.3 FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.1.4 FUJIFILM HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 FUJIFILM Recent Developments and Future Plans
  • 2.2 Eli Lilly and Company
    • 2.2.1 Eli Lilly and Company Details
    • 2.2.2 Eli Lilly and Company Major Business
    • 2.2.3 Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.2.4 Eli Lilly and Company HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Eli Lilly and Company Recent Developments and Future Plans
  • 2.3 Fujirebio
    • 2.3.1 Fujirebio Details
    • 2.3.2 Fujirebio Major Business
    • 2.3.3 Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.3.4 Fujirebio HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Fujirebio Recent Developments and Future Plans
  • 2.4 Roche Diagnostics
    • 2.4.1 Roche Diagnostics Details
    • 2.4.2 Roche Diagnostics Major Business
    • 2.4.3 Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.4.4 Roche Diagnostics HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Roche Diagnostics Recent Developments and Future Plans
  • 2.5 Fapon Biotech
    • 2.5.1 Fapon Biotech Details
    • 2.5.2 Fapon Biotech Major Business
    • 2.5.3 Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.5.4 Fapon Biotech HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Fapon Biotech Recent Developments and Future Plans
  • 2.6 Labcorp
    • 2.6.1 Labcorp Details
    • 2.6.2 Labcorp Major Business
    • 2.6.3 Labcorp HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.6.4 Labcorp HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Labcorp Recent Developments and Future Plans
  • 2.7 Thermo Fisher Scientific
    • 2.7.1 Thermo Fisher Scientific Details
    • 2.7.2 Thermo Fisher Scientific Major Business
    • 2.7.3 Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.7.4 Thermo Fisher Scientific HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Thermo Fisher Scientific Recent Developments and Future Plans
  • 2.8 Abcam
    • 2.8.1 Abcam Details
    • 2.8.2 Abcam Major Business
    • 2.8.3 Abcam HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.8.4 Abcam HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Abcam Recent Developments and Future Plans
  • 2.9 Bio-Techne
    • 2.9.1 Bio-Techne Details
    • 2.9.2 Bio-Techne Major Business
    • 2.9.3 Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.9.4 Bio-Techne HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Bio-Techne Recent Developments and Future Plans
  • 2.10 MyBiosource
    • 2.10.1 MyBiosource Details
    • 2.10.2 MyBiosource Major Business
    • 2.10.3 MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.10.4 MyBiosource HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 MyBiosource Recent Developments and Future Plans
  • 2.11 RayBiotech
    • 2.11.1 RayBiotech Details
    • 2.11.2 RayBiotech Major Business
    • 2.11.3 RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.11.4 RayBiotech HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 RayBiotech Recent Developments and Future Plans
  • 2.12 CUSABIO
    • 2.12.1 CUSABIO Details
    • 2.12.2 CUSABIO Major Business
    • 2.12.3 CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.12.4 CUSABIO HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 CUSABIO Recent Developments and Future Plans
  • 2.13 Elabscience Biotechnology
    • 2.13.1 Elabscience Biotechnology Details
    • 2.13.2 Elabscience Biotechnology Major Business
    • 2.13.3 Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.13.4 Elabscience Biotechnology HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Elabscience Biotechnology Recent Developments and Future Plans
  • 2.14 Abbexa
    • 2.14.1 Abbexa Details
    • 2.14.2 Abbexa Major Business
    • 2.14.3 Abbexa HCC (Hepatocellular Carcinoma) Biomarker Product and Solutions
    • 2.14.4 Abbexa HCC (Hepatocellular Carcinoma) Biomarker Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Abbexa Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global HCC (Hepatocellular Carcinoma) Biomarker Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of HCC (Hepatocellular Carcinoma) Biomarker by Company Revenue
    • 3.2.2 Top 3 HCC (Hepatocellular Carcinoma) Biomarker Players Market Share in 2025
    • 3.2.3 Top 6 HCC (Hepatocellular Carcinoma) Biomarker Players Market Share in 2025
  • 3.3 HCC (Hepatocellular Carcinoma) Biomarker Market: Overall Company Footprint Analysis
    • 3.3.1 HCC (Hepatocellular Carcinoma) Biomarker Market: Region Footprint
    • 3.3.2 HCC (Hepatocellular Carcinoma) Biomarker Market: Company Product Type Footprint
    • 3.3.3 HCC (Hepatocellular Carcinoma) Biomarker Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global HCC (Hepatocellular Carcinoma) Biomarker Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global HCC (Hepatocellular Carcinoma) Biomarker Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global HCC (Hepatocellular Carcinoma) Biomarker Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global HCC (Hepatocellular Carcinoma) Biomarker Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Type (2021-2032)
  • 6.2 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Application (2021-2032)
  • 6.3 North America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country
    • 6.3.1 North America HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Country (2021-2032)
    • 6.3.2 United States HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 6.3.3 Canada HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Type (2021-2032)
  • 7.2 Europe HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Application (2021-2032)
  • 7.3 Europe HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country
    • 7.3.1 Europe HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Country (2021-2032)
    • 7.3.2 Germany HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 7.3.3 France HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 7.3.5 Russia HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 7.3.6 Italy HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Market Size by Region
    • 8.3.1 Asia-Pacific HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Region (2021-2032)
    • 8.3.2 China HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 8.3.3 Japan HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 8.3.5 India HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 8.3.7 Australia HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Type (2021-2032)
  • 9.2 South America HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Application (2021-2032)
  • 9.3 South America HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country
    • 9.3.1 South America HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Market Size by Country
    • 10.3.1 Middle East & Africa HCC (Hepatocellular Carcinoma) Biomarker Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)
    • 10.3.4 UAE HCC (Hepatocellular Carcinoma) Biomarker Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 HCC (Hepatocellular Carcinoma) Biomarker Market Drivers
  • 11.2 HCC (Hepatocellular Carcinoma) Biomarker Market Restraints
  • 11.3 HCC (Hepatocellular Carcinoma) Biomarker Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 HCC (Hepatocellular Carcinoma) Biomarker Industry Chain
  • 12.2 HCC (Hepatocellular Carcinoma) Biomarker Upstream Analysis
  • 12.3 HCC (Hepatocellular Carcinoma) Biomarker Midstream Analysis
  • 12.4 HCC (Hepatocellular Carcinoma) Biomarker Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global HCC (Hepatocellular Carcinoma) Biomarker market size was valued at US$ 969 million in 2025 and is forecast to a readjusted size of US$ 1456 million by 2032 with a CAGR of 6.1% during review period.
    Hepatocellular carcinoma (HCC) is the seventh most common cancer diagnosis worldwide with high associated mortality. HCC is a unique malignancy, as it typically arises in the setting of chronic liver disease in particular cirrhosis, with competing risks of liver failure, contributing to its low 5-year survival rates of 18%–20%. More than half of worldwide HCC-related deaths occur in Asia, due to endemic hepatitis B (HBV) infection. HCC incidence is rising in many Western countries due to the rising prevalence of nonalcoholic fatty liver disease, alcohol-related liver disease, and hepatitis C (HCV)-related complications despite the availability of direct acting antiviral therapies. The search for biomarkers in hepatocellular carcinoma continues despite recent approvals for immune checkpoint inhibitor combinations, tyrosine kinase inhibitors [TKIs], and antiangiogenesic agents. Biomarkers can be either predictive or prognostic and the only biomarker that has been used clinically is the prognostic biomarker α-fetoprotein (AFP).
    This report is a detailed and comprehensive analysis for global HCC (Hepatocellular Carcinoma) Biomarker market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global HCC (Hepatocellular Carcinoma) Biomarker market size and forecasts, in consumption value ($ Million), 2021-2032
    Global HCC (Hepatocellular Carcinoma) Biomarker market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global HCC (Hepatocellular Carcinoma) Biomarker market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global HCC (Hepatocellular Carcinoma) Biomarker market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for HCC (Hepatocellular Carcinoma) Biomarker
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global HCC (Hepatocellular Carcinoma) Biomarker market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include FUJIFILM, Eli Lilly and Company, Fujirebio, Roche Diagnostics, Fapon Biotech, Labcorp, Thermo Fisher Scientific, Abcam, Bio-Techne, MyBiosource, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    HCC (Hepatocellular Carcinoma) Biomarker market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Alpha-fetoprotein (AFP)
    Des-γ-carboxy Prothrombin (DCP)
    Others
    Market segment by Application
    Hospitals
    Clinics
    Others
    Market segment by players, this report covers
    FUJIFILM
    Eli Lilly and Company
    Fujirebio
    Roche Diagnostics
    Fapon Biotech
    Labcorp
    Thermo Fisher Scientific
    Abcam
    Bio-Techne
    MyBiosource
    RayBiotech
    CUSABIO
    Elabscience Biotechnology
    Abbexa
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe HCC (Hepatocellular Carcinoma) Biomarker product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of HCC (Hepatocellular Carcinoma) Biomarker, with revenue, gross margin, and global market share of HCC (Hepatocellular Carcinoma) Biomarker from 2021 to 2026.
    Chapter 3, the HCC (Hepatocellular Carcinoma) Biomarker competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and HCC (Hepatocellular Carcinoma) Biomarker market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of HCC (Hepatocellular Carcinoma) Biomarker.
    Chapter 13, to describe HCC (Hepatocellular Carcinoma) Biomarker research findings and conclusion.

    Buy now